Holen Sie sich die Stockscreener-App
3.94
6.78%
0.25
Handel nachbörslich:
3.89
-0.05
-1.27%
Schlusskurs vom Vortag:
$3.69
Offen:
$3.69
24-Stunden-Volumen:
72,527
Relative Volume:
3.42
Marktkapitalisierung:
$5.78M
Einnahmen:
$2.54M
Nettoeinkommen (Verlust:
$-4.13M
KGV:
-1.3633
EPS:
-2.89
Netto-Cashflow:
$-4.11M
1W Leistung:
-0.25%
1M Leistung:
+3.14%
6M Leistung:
+9.20%
1J Leistung:
+23.12%
1-Tages-Spanne:
$3.58
$4.00
1-Wochen-Bereich:
$3.58
$4.43
52-Wochen-Spanne:
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Firmenname
Xenetic Biosciences Inc
Sektor
Branche
Telefon
781-778-7720
Adresse
945 CONCORD ST., FRAMINGHAM, MA
Vergleichen Sie XBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| XBIO | 3.94 | 5.78M | 2.54M | -4.13M | -4.11M | -2.89 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-08 | Eingeleitet | Maxim Group | Buy |
Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
Xenetic presents preclinical data on DNase platform technology - TipRanks
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick
Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan
Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World
Xenetic extends research collaboration with Scripps Research Institute - TipRanks
Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire
Xenetic Biosciences announces board member changes - Investing.com India
Xenetic Biosciences announces board member changes By Investing.com - Investing.com UK
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire
SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire
Xenetic partners with Tokyo Medical for cancer treatment study - Investing.com
Secondary Progressive Multiple Sclerosis Drug Market to Expand with Significant CAGR by 2034 |AB Science SA, Actelion Lt – IndiaPolitics.com - IndiaPolitics.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 50.0% - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Kansas City Star
Q3 2024 Earnings Estimate for Xenetic Biosciences Inc (NASDAQ:XBIO) Issued By HC Wainwright - Defense World
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 - MSN
Xenetic Biosciences (NASDAQ:XBIOW) Stock Price Up 33.9% - Defense World
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St
Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Hits Estimates - Defense World
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Markets Insider
Xenetic Biosciences: Q2 Earnings Snapshot - CTPost
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 3,550.0% in July - Defense World
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Xenetic Biosciences stock hits 52-week low at $2.78 By Investing.com - Investing.com Canada
Xenetic Biosciences stock hits 52-week low at $2.78 - Investing.com India
Takeda Pharmaceutical (TAK) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Xenetic Biosciences Inc-Aktie (XBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):